Warning Letter — Pritam International Private Limited
The FDA issued a warning letter to Pritam International Private Limited following an inspection that identified significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.
This notice affects Pritam International Private Limited, as well as personnel involved in drug manufacturing, quality control, and regulatory compliance at the facility.
The issuance of a warning letter by CDER indicates that the facility's quality systems failed to meet minimum federal standards for drug production. This typically leads to increased regulatory scrutiny, potential import alerts if the facility is outside the U.S., and the requirement for a comprehensive corrective and preventive action (CAPA) plan to address systemic manufacturing deficiencies.
Firms should verify that all finished drug products meet compendial or internal quality specifications prior to release and ensure that all manufacturing deviations are documented and investigated. Quality units must maintain oversight of production records to ensure full compliance with Current Good Manufacturing Practice (CGMP).
FDA Warning Letter issued to: Pritam International Private Limited. 10/27/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026
Open in openFDA / FDA.gov